Jul 17, 2020
Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
Jul 14, 2020
TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
May 18, 2020
Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations
Apr 24, 2020
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
Apr 21, 2020
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Mar 28, 2020
Landmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
Mar 18, 2020
Janssen Submits Ponesimod New Drug Application to the U.S. FDA for Treatment of Adults with Relapsing Multiple Sclerosis
Mar 02, 2020
European Medicines Agency Grants PRIME and Advanced Therapy Medicinal Product Designations to Janssen's RPGR Gene Therapy for X-Linked Retinitis Pigmentosa
Feb 25, 2020
Johnson & Johnson Launches Heartline(TM), the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
Feb 06, 2020
Fourth Annual Blue Jacket Fashion Show Included David Byrne, André Leon Talley, Dr. Mehmet Oz, Bill Nye And More for Men's Health And Prostate Cancer Awareness
Feb 03, 2020
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
Dec 30, 2019
Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.
Dec 21, 2019
Complete Response Letter Issued from U.S. FDA for Investigational Long-Acting HIV Regimen
Dec 09, 2019
DARZALEX® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant
Dec 07, 2019
Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma
Dec 07, 2019
Janssen to Acquire Investigational Bermekimab from XBiotech
Nov 11, 2019
TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies
Nov 09, 2019
New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA® (canagliflozin) are Consistent Across Various Levels of Kidney Function
Oct 31, 2019
Janssen Presenting Data From Its Expanding Rheumatology Portfolio At The 2019 Annual Meeting Of The American College Of Rheumatology
Oct 21, 2019
STELARA® (ustekinumab) Data Demonstrate Long-Term Efficacy and Safety Results in Adults with Moderately to Severely Active Ulcerative Colitis in Phase 3 Extension Trial